How Citigroup Currently Rates FibroGen (NASDAQ:FGEN)
Citigroup began coverage on FibroGen (NASDAQ:FGEN) shares recently in analysts report shared with investors on Friday, 4 December. The financial firm has decided to place a “Buy” rating on FGEN stock.
From a total of 5 analysts covering FibroGen Inc (NASDAQ:FGEN) stock, 5 rate it a ”Buy”, 0 a “Sell”, and 1 a ”Hold”. This means that 83% of the ratings are positive. The highest target price is $52 while the lowest target price is $25. The mean of all analyst targets is $37.6 with a 2.75% above today’s ($30.17) stock price. FibroGen Inc was the topic of 2 analyst reports since July 29, 2015 according to the firm StockzIntelligence Inc. Lake Street initiated shares on September 23 with “Hold” rating.
Approximately 89,570 shares of stock traded hands. FibroGen Inc (NASDAQ:FGEN) has risen 25.58% since May 1, 2015 and is uptrending. It has outperformed by 28.36% the S&P500.
FibroGen, Inc. is a research-based, biopharmaceutical company. The company has a market cap of $1.85 billion. The Firm is focused on the discovery, development and commercialization of therapeutic agents. It currently has negative earnings. The Company’s lead product candidate is roxadustat, or FG-4592 is an oral small molecule inhibitor of hypoxia inducible factor-prolyl hydroxylase , in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD).
According to Zacks Investment Research, “FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California.” Get a free copy of the Zacks research report on FibroGen Inc (FGEN).